| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Sáez-Valero, S S Mok, D H Smal. An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. Acta neurologica Scandinavica. Supplementum. vol 176. 2001-05-17. PMID:11261805. |
an unusually glycosylated form of acetylcholinesterase is a csf biomarker for alzheimer's disease. |
2001-05-17 |
2023-08-12 |
Not clear |
| N H Greig, E De Micheli, H W Holloway, Q S Yu, T Utsuki, T A Perry, A Brossi, D K Ingram, J Deutsch, D K Lahiri, T T Soncran. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta neurologica Scandinavica. Supplementum. vol 176. 2001-05-17. PMID:11261809. |
phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (ache) inhibitor, with a > 50-fold activity versus butyrylcholinesterase (bche), in clinical trials for the treatment of alzheimer's disease (ad). |
2001-05-17 |
2023-08-12 |
rat |
| N Tanaka, K Fukushi, H Shinotoh, S Nagatsuka, H Namba, M Iyo, A Aotsuka, T Ota, S Tanada, T Iri. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 21. issue 3. 2001-04-26. PMID:11295884. |
positron emission tomographic measurement of brain acetylcholinesterase activity using n-[(11)c]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for alzheimer's disease. |
2001-04-26 |
2023-08-12 |
human |
| R S Doody, D S Geldmacher, B Gordon, C A Perdomo, R D Prat. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of neurology. vol 58. issue 3. 2001-04-05. PMID:11255446. |
donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe alzheimer disease (ad). |
2001-04-05 |
2023-08-12 |
Not clear |
| B Borroni, F Colciaghi, L Pastorino, C Pettenati, E Cottini, L Rozzini, R Monastero, G L Lenzi, F Cattabeni, M Di Luca, A Padovan. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Archives of neurology. vol 58. issue 3. 2001-04-05. PMID:11255448. |
amyloid precursor protein in platelets of patients with alzheimer disease: effect of acetylcholinesterase inhibitor treatment. |
2001-04-05 |
2023-08-12 |
human |
| S Dronfield, K Egan, C A Marsden, A R Gree. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. Journal of psychopharmacology (Oxford, England). vol 14. issue 3. 2001-03-29. PMID:11106308. |
there are now several acetylcholinesterase inhibitors in clinical use for the treatment of alzheimer's disease, however, no systematic comparative studies of their central and peripheral cholinergic mediated effects in rats appear to have been reported. |
2001-03-29 |
2023-08-12 |
rat |
| S Dronfield, K Egan, C A Marsden, A R Gree. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. Journal of psychopharmacology (Oxford, England). vol 14. issue 3. 2001-03-29. PMID:11106308. |
the data are consistent with clinical results and indicate that simple in-vivo models may assist in the selection of acetylcholinesterase inhibitors with a suitable response profile for use in the symptomatic treatment of alzheimer's disease. |
2001-03-29 |
2023-08-12 |
rat |
| F Villatte, T T Bachman, A S Hussein, R D Schmi. Acetylcholinesterase assay for rapid expression screening in liquid and solid media. BioTechniques. vol 30. issue 1. 2001-03-29. PMID:11196324. |
the synaptic enzyme acetylcholinesterase (ache), which is the target of many insecticides and potential warfare agents, is implied in alzheimer's disease and is a good potential candidate to be used in biosensors. |
2001-03-29 |
2023-08-12 |
Not clear |
| S E Snyder, N Gunupudi, P S Sherman, E R Butch, M B Skaddan, M R Kilbourn, R A Koeppe, D E Kuh. Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 21. issue 2. 2001-03-08. PMID:11176278. |
there is currently great interest in developing radiolabeled substrates for acetylcholinesterase and butyrylcholinesterase that would be useful in the in vivo imaging of patients with alzheimer's disease. |
2001-03-08 |
2023-08-12 |
mouse |
| M B Skaddan, M R Kilbourn, S E Snyder, P S Sherma. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 21. issue 2. 2001-03-08. PMID:11176279. |
although the inhibition of acetylcholinesterase remains the primary treatment of alzheimer's disease, little is known of the results of increased acetylcholine levels on muscarinic receptor occupancy or function. |
2001-03-08 |
2023-08-12 |
rat |
| P Kasa, H Papp, P Kasa, I Toro. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience. vol 101. issue 1. 2001-02-15. PMID:11068139. |
in the symptomatic treatment of mild to moderately severe dementia associated with alzheimer's disease, donepezil (e2020) has been introduced for the inhibition of acetylcholinesterase activity in the human brain. |
2001-02-15 |
2023-08-12 |
human |
| J J Sramek, N R Cutle. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer disease and associated disorders. vol 14. issue 4. 2001-02-08. PMID:11186600. |
red blood cell (rbc) acetylcholinesterase (ache) inhibition has been used as a peripheral surrogate marker for the activity of centrally acting ache inhibitors (acheis) in the treatment of alzheimer disease. |
2001-02-08 |
2023-08-12 |
human |
| L J Scott, K L Go. Galantamine: a review of its use in Alzheimer's disease. Drugs. vol 60. issue 5. 2001-02-01. PMID:11129124. |
currently, acetylcholinesterase (ache) inhibitors are the most promising class of drugs for the treatment of alzheimer's disease (ad). |
2001-02-01 |
2023-08-12 |
Not clear |
| Y H Zhang, X Q Chen, H H Yang, G Y Jin, D L Bai, G Y H. Similar potency of the enantiomers of huperzine A in inhibition of [(3)H]dizocilpine (MK-801) binding in rat cerebral cortex. Neuroscience letters. vol 295. issue 3. 2001-01-18. PMID:11090988. |
the inhibition of huperzine a, a potential therapeutic agent to treat alzheimer's disease, on rat cortical acetylcholinesterase was found to be highly stereospecific. |
2001-01-18 |
2023-08-12 |
rat |
| H W Querfurth, G J Allam, M A Geffroy, H B Schiff, R F Kapla. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dementia and geriatric cognitive disorders. vol 11. issue 6. 2001-01-08. PMID:11044776. |
the response to acetylcholinesterase inhibition (achei) could be greater in dlb than in alzheimer's disease (ad) because cholineacetyl-transferase levels are more reduced in the former. |
2001-01-08 |
2023-08-12 |
human |
| K K Jai. Evaluation of memantine for neuroprotection in dementia. Expert opinion on investigational drugs. vol 9. issue 6. 2001-01-08. PMID:11060751. |
it can be combined with acetylcholinesterase inhibitors which are the mainstay of current symptomatic treatment of alzheimer's disease. |
2001-01-08 |
2023-08-12 |
Not clear |
| H J Heo, H C Yang, H Y Cho, B Hong, S T Lim, H J Park, K H Kim, H K Kim, D H Shi. Inhibitory effect of Artemisia asiatica alkaloids on acetylcholinesterase activity from rat PC12 cells. Molecules and cells. vol 10. issue 3. 2000-12-28. PMID:10901162. |
we screened 42 korean traditional tea plants to determine the inhibitory effect of acetylcholinesterase and attenuation of toxicity induced by amyloid-beta peptide, which were related to the treatment of alzheimer's disease (ad). |
2000-12-28 |
2023-08-12 |
human |
| H J Heo, H C Yang, H Y Cho, B Hong, S T Lim, H J Park, K H Kim, H K Kim, D H Shi. Inhibitory effect of Artemisia asiatica alkaloids on acetylcholinesterase activity from rat PC12 cells. Molecules and cells. vol 10. issue 3. 2000-12-28. PMID:10901162. |
this study demonstrated that an alkaloid of artemisia asiatica, which was metabolized to small molecule in digestive tract and then could pass through the blood-brain barrier, appeared to be an acetylcholinesterase inhibitor with a blocker of neurotoxicity induced by a beta in human brain causing alzheimer's disease. |
2000-12-28 |
2023-08-12 |
human |
| S Lilienfeld, W Pary. Galantamine: additional benefits to patients with Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 11 Suppl 1. 2000-12-28. PMID:10971048. |
galantamine, a novel treatment for alzheimer's disease (ad), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase. |
2000-12-28 |
2023-08-12 |
Not clear |
| M Windisc. Approach towards an integrative drug treatment of Alzheimer's disease. Journal of neural transmission. Supplementum. vol 59. 2000-12-22. PMID:10961442. |
at present pharmacotherapy of alzheimer's disease (ad) is limited to acetylcholinesterase inhibitors. |
2000-12-22 |
2023-08-12 |
Not clear |